[PDF] Top 20 Os direitos humanos no mundo lusófono: o estado da arte
Has 10000 "Os direitos humanos no mundo lusófono: o estado da arte" found on our website. Below are the top 20 most common "Os direitos humanos no mundo lusófono: o estado da arte".
Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
... As the COG ANBL0032 randomized Phase III clinical trial employed ch14.18 together with GM-CSF and IL-2 and interspersed with 13-cis-RA, the relative contribution of the various components of maintenance therapy ... See full document
9
Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
... Brodalumab, a human antiinterleukin-17 receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase 2 random[r] ... See full document
5
Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
... Abstract: Epithelial ovarian cancer is the sixth most common cancer among women worldwide and the first cause of death among gynecological malignancies. Most of the patients present recurrent disease and unfortunately ... See full document
32
Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy
... outpatient treatment, and the dosing regimen is similar to azithromycin; so its proper use will be familiar to many healthcare ...need treatment for pneumonia, and it has a ... See full document
23
Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy
... necessitating treatment in only those children with ongoing bleeding manifestations or impairment in health-related quality of life ...the development of a new class of agents, the TPO-receptor agonists ... See full document
7
Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
... nivolumab plus ipilimumab (CheckMate-016) initially tested three different dosing schedules: nivolumab 1 mg/kg + ipili- mumab 3 mg/kg (Nivo 1 + Ipi 3), nivolumab 3 mg/kg + ipili- mumab 1 mg/kg (Nivo 3 + Ipi 1), and ... See full document
21
Spotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapy
... the treatment of asthmatic patients, and international guidelines have designated ICSs as an early maintenance therapy in controlling asthma ...combination therapy with the ICS fluticasone furoate ... See full document
6
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
... the treatment of ALK-positive NSCLC patients with progres- sion, or who are intolerant to crizotinib, based on pronounced clinical activity observed in the Phase I ASCEND-1 trial, and it is currently approved in ... See full document
24
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
... adjusted treatment difference - ...Overall treatment response at the end of treatment – including clinical, mycological, and radio- logical responses – and mortality at day 84 were similar in both ... See full document
29
Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy
... little treatment- related toxicity, and potentially confers a survival ...increased risk for infusion reaction, neutropenia, mucositis, as well as the extra visit needed for a day 8 infusion when receiving ... See full document
14
Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy
... Abstract: Atopic dermatitis (AD) is among the most common inflammatory skin diseases in children and adults in industrialized countries. Up to one-third of adults (probably a smaller proportion in childhood) suffer from ... See full document
8
Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy
... Considering Phase III data only, irritability (3%, 4%, 7% and 12% with placebo, 4, 8 and 12 mg/day respectively), and aggression (1% with placebo and 4 mg/day, 2% with 8 mg/day and 3% with 12 mg/day) both appeared to ... See full document
11
Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
... of therapy should be discussed with the patient taking into account neo- natal risks and the risk of disease ...the treatment of these patients, is there any advantage to use CZP? Some CZP features, ... See full document
5
Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
... the treatment of a range of psychiatric disorders, differ substantially in terms of their pharmacology and adverse effect ...prompt development of new ...the treatment of schizophrenia and as an ... See full document
22
Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
... events. Treatment with siponimod was associated with 21% reduction in the risk of disability progression confirmed at 3 months (26% at 6 months) compared to placebo (hazard ratio = ...siponimod ... See full document
10
Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
... higher dose blisibimod (100 mg and 200 mg once weekly), exceeding the minimal clinically important difference in SLE (P,0.05). SRI-5 responders had significantly higher mean changes in fatigue compared with ... See full document
6
Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
... the treatment of patients with RRMM who have received one to three prior therapies (US Food and Drug Administration [FDA]) or 1 prior therapy (European Medicines Agency ...previous treatment ... See full document
156
Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis
... capacity values. Interestingly, TCZ treatment resulted in downregulation of genes associated with M2 macrophages in skin biopsies. Serious infections were more common in the TCZ group (16%) than in the placebo ... See full document
6
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
... Ertugliflozin efficacy has also been evaluated as add-on or combination therapy with sitagliptin and metformin. The VERTIS MET trial investigated the efficacy and safety of ertugliflozin, versus placebo, in ... See full document
6
Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections
... revealed that 200 mg of posaconazole on day 1 followed by 100 mg daily was noninferior to 200 mg of fluconazole on day 1 followed by 100 mg daily. Both medications were administered with food. After 14 days of ... See full document
12
Related subjects